Focus: Becton Dickinson is a 50,000+ person public medical device company headquartered in New Jersey, generating $19.4B in FY2025 revenue across infection prevention, vascular access, diabetes management, and diagnostic systems.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Hot — 614 jobs added in 30d
Net +172 (614 new, 442 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 238 affected
Source: state DOL filings via Big Local News
A stable, cash-generative device giant offering strong operational careers, but limited R&D upside and alarming revenue concentration warrant due diligence before joining R&D or strategy functions.
Antimicrobial oral rinse in pre-launch phase; represents core revenue concentration reported by company, but lifecycle status suggests either new formulation or market entry lag.
Help build intelligence for Becton Dickinson
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Becton Dickinson's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Surgical prep swab approaching loss of exclusivity in April 2027; part of the CHLORAPREP platform that dominates BD's infection prevention revenue.
Currently at peak sales but LOE approaching in January 2026; major revenue cliff imminent as generic/biosimilar competition enters.
Surgical scrub with imminent loss of exclusivity; limited clinical data available in pipeline suggests legacy product.
4 discontinued, 11 duplicate formulations not shown
Becton Dickinson Is Down 30% From Its 52-Week High. Is It Still a Buy in 2026? - TIKR.com
Becton Dickinson Is Down 30% From Its 52-Week High. Is It Still a Buy in 2026? TIKR.com
Becton Dickinson stock (US0718131099): Earnings update and long-term healthcare demand - AD HOC NEWS
Becton Dickinson stock (US0718131099): Earnings update and long-term healthcare demand AD HOC NEWS
Healthcare suppliers bullish on plastics demand tied to injectable drugs - Plastics News
Healthcare suppliers bullish on plastics demand tied to injectable drugs Plastics News
Becton Dickinson Stock (US0718131099): Analyst Upgrade to Buy on GLP-1 Demand Boost - AD HOC NEWS
Becton Dickinson Stock (US0718131099): Analyst Upgrade to Buy on GLP-1 Demand Boost AD HOC NEWS
Becton Dickinson raises 2026 profit forecast on drug delivery devices demand - ETPharma.com
Becton Dickinson raises 2026 profit forecast on drug delivery devices demand ETPharma.com
Becton Dickinson raises annual profit forecast on strength in drug delivery devices - MSN
Becton Dickinson raises annual profit forecast on strength in drug delivery devices MSN
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Treating native arteries, bypasses and in-stent-restenosis with rotational athero-thrombectomy - two-year results from the Rotarex-PMCF trial.
Design Differences and Usability Risks in GLP-1 Pen Injectors: A Comparative Study of a Generic and Reference Device.
Source: state DOL filings, aggregated via Big Local News
No recent WARN Act filings, FDA warnings, or public layoffs; operational stability appears intact, but patent cliff exposure (2026-2027) and revenue concentration present latent restructuring risk.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo